Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial

NCT03873311 is registered in ClinicalTrials.gov with Shenzhen Second People's Hospital as lead sponsor.

NCT NCT03873311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03873311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Azacytidine Combined With HAG Regimen Versus Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy: a Prospective, Randomized Controlled Trial
Lead sponsor
Shenzhen Second People's Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
September 1, 2019
Completion date
June 1, 2023
Enrollment
114 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia; myelodysplastic syndromes;chronic myelomonocytic leukemia